

# Subscribe for long Term

## Rating: Subscribe for Long Term

#### **Issue Offer**

Fresh Issue of 108,108,108 Equity shares aggregating up to INR 8000 Mn and OFS of 189,189,189 shares by the Promoters group taking the total issue size at INR 14000 Mn

Issue Summary	
Price Band (INR)	70-74
Face Value (INR)	10
Implied Market Cap	
(INR mn.)	135,200
Market Lot	200
Issue Opens on	Nov,7,2024
Issue Close on	Nov,11,2024
No. of share pre-issue	1,718,918,290
No. of share pre-issue	1,827,026,398
Listing	BSE,NSE
Issue Break-up (%)	
QIB Portion	75%
Retail Portion	10%
NII Portion	15%

## Registrar

Kfin Technologies Limited

### **Book Running Lead Managers**

ICICI Securities limited

Morgan Stanley India Company Pvt Ltd.

Kotak Mahindra Capital Company Ltd.

Axis Capital Limited

**HDFC Bank Limited** 

Motilal Oswal Investment Advisors Ltd.

Shareholding Pattern			
	Pre-Issue	Post-Issue	
Promoters	89.07%	73.44%	
Public & Others	10.93%	26.56 %	

### Objects of the issue

- Augmentation of its capital base to strengthen solvency levels
- General corporate purposes

# Abhishek Jain

abhishek.jain@arihantcapital.com 022-422548871

#### Natasha Singh

natasha.singh@arihantcapital.com 022-42254876 Niva Bupa Health Insurance Co. Ltd. is one of India's leading health insurers, dedicated to empowering individuals with the confidence to access quality healthcare. Supported by the Bupa Group, NBHICL has built a comprehensive health ecosystem offering insurance products and digital tools like the "Niva Bupa Health" app, which provides customers with access to diagnostics, digital consultations, health check-ups, and seamless claims management. NBHICL stands out for its innovative products like "Reassure" and "Aspire," featuring unique "industry-first" benefits such as "2 Hours Hospitalization" and "Unlimited Reinstatement" of the insured sum. This customer-centric approach, driven by product innovation, enhances the overall experience by providing coverage flexibility and a broad suite of wellness tools.

#### **Investment Rationale**

Generating strong GWP growth, capital efficiency, and profitability: The company, ranked as the third largest and second fastest-growing SAHI (Standalone Health Insurance) player in India robust GWP growth with a CAGR of 41.37% from FY22-24. Its market share in the SAHI segment was 17.29% as of August 24, consistently closing the gap with larger competitors while distancing itself from smaller peers. Focusing on high-LTV and high-margin retail health products, the average ticket size increased from INR 22,186.45 in FY22 to INR 30,419.06 in Q1 of FY25. Active lives insured grew by 102% to 14.73Mn by March 24, indicating significant expansion. The company improved its Claims Ratio from 62.12% in FY22 to 59.02% inFY24, and reduced Expense of Management as a percentage of GWP to 39.31% in FY24, enhancing operational efficiency. Profitability also turned around, with a profit of INR 818.52Mn in FY24, driven by higher underwriting efficiency and cost control. Additionally, the company's AUM grew to INR 56,744.43Mn as of June24, with improved investment yields.

Customer-Centric Growth Through Product Innovation in Health Insurance: Company health insurance portfolio, designed with a customer-centric approach, prioritizes innovation and tailored offerings to meet the diverse needs across customer lifecycles. Their leading products, like "Reassure" for affluent customers and the newly launched "Aspire" targeting Millennials and Gen Z, feature unique benefits such as "Booster+" for balance sum insured and "Lock the Clock" for age-based premium consistency. Backed by the Redseer Report, their products include "industry-first" features like "2 Hours Hospitalization" and unlimited sum reinstatement, setting us apart in the market. Through continuous product innovation and data-driven customer lifecycle value (LTV) analysis.

Technology-Driven Automation Enhancing Customer Experience in Health Insurance: Technology-led automation in customer service has streamlined their processes, delivering a seamless self-serve experience with minimal manual intervention. In FY24, 99.95% of new policies were digitally processed via their website and mobile apps, reflecting adaptability to customers' preference for digital engagement. Through innovations like auto-underwriting system, chatbot "Cia" with Al-driven conversational capabilities, and the "Insta Assist" portal, Company offer customers instant access to policy details and self-service options. Collaborations with Vitraya Technologies have enabled Al-led, paperless claims processing, enhancing accuracy and speed with auto-adjudication and document digitization. These advancements, supported by Al and analytics, ensure an efficient and customer-friendly insurance experience.

Strategic Expansion and Channel Diversification for Retail Health Insurance Growth: Company strategy focuses on expanding their retail health insurance market share across India by deepening the distribution channels and enhancing their presence in both urban and rural areas. Company plan to increase their footprint by opening new branches in existing districts, expanding branches to support more agents, and establishing a stronger presence in smaller towns and Tier-2 cities. Alongside this, they are strengthening their digital distribution through web aggregators, digital brokers, and direct-to-customer channels. A key growth driver is eagency model, which enables agent recruitment in regions without physical branches, supported by their "Niva Bupa UNO" app and remote training programs. By enhancing technology infrastructure and support for agents, they aim to drive substantial retail health insurance growth nationwide.

Valuation and View: Niva Bupa Health Insurance Co. Ltd. has positioned itself as India's third largest and second fastest-growing standalone health insurer, achieving robust GWP growth at a 41.37% CAGR from FY22-24 and a 17.29% market share as of August 2024. The company focuses on high-LTV retail health products with an increasing average ticket size and significant expansion in active lives insured. Operational efficiencies have improved, with a reduced Claims Ratio and Expense of Management, driving profitability to INR 818.52Mn in FY24. NBHICL emphasizes customer-centric innovation with unique offerings like "Reassure" and "Aspire," and leverages technology-led automation, including Al-driven claims processing, to enhance the customer experience. Strategic expansion across India and digital channel growth, supported by the e-agency model, further strengthen its retail health market reach. At the upper band of INR 74, the issue is valued at a PBV ratio of 6.1x based on a FY24 BV of INR 12.06 We are recommending a "Subscribe for Long Term" for this issue.

# **Arihant Research Desk**

Email: instresearch@arihantcapital.com

Tel.: 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park	
Building No. 10, 1 <sup>st</sup> Floor	6 Lad Colony
Andheri Ghatkopar Link Road	Y.N Road
Chakala, Andheri (E)	Indore - 452003, (M.P.)
Mumbai – 400093	Tel: 0731-4217100
Tel: (91-22) 42254800	Fax: (91-731) 3016199
Fax: (91-22) 42254880	

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	www.arihantcapital.com	instresearch@arihantcapital. com

Disclaimer: This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd. 1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E) Tel. 022-42254800Fax. 022-42254880